10 Mistakes PCD Companies Make With Third-Party Manufacturing (and the Red Flags)

Most third-party manufacturing arrangements do not fail dramatically. They fail quietly, in month nine, over something that was visible in week one and nobody looked at. Here are the mistakes that actually cost people money — and the red flags that predict them.

If you want the checklist version, read how to choose a drug manufacturing company. This page is the other half: what goes wrong.

Mistake 1 — Asking for the rate before the certificate

Almost everyone does this, and it is the root of most of what follows. A rate tells you nothing until you know which plant is making the medicine and whether that plant is certified for your dosage form. Certificate first. Rate second. If that order feels awkward to the person you are talking to, that is your first data point.

Mistake 2 — Accepting "we are WHO-GMP certified" as an answer

Red flag: any certification claim without a site name.

WHO-GMP is issued to premises, not companies. The document is headed "Site Certificate" and names one address. So the claim "we are WHO-GMP certified" can be entirely true and still tell you nothing about who made your medicine — a marketing firm can say it while the certified site belongs to someone else entirely.

Ask: which site, at what address, certified for which forms, under which licence number, valid until when.

Mistake 3 — Not asking whose licence your product is made under

Red flag: vagueness about ownership. "Our facilities." "Our associated units." "Our manufacturing partners."

Plenty of companies offering third-party manufacturing do not own a plant — they take your order and place it with someone who does. That is not automatically wrong. But it decides who you can actually call when a batch is late, short or wrong, and it usually means a margin in between. Ask the question directly. The licence number ends up printed on your pack either way.

Mistake 4 — Comparing quotes that are not comparable

Rates move with composition, order quantity, packing specification, and whether you supply packing material. Two quotes are only comparable when all four match. Most people compare a per-unit number across four manufacturers who quoted on four different bases, then pick the lowest and wonder why it was not the cheapest.

Mistake 5 — Ignoring the MOQ until it is too late

Red flag: a rate quoted without a batch size attached to it.

The minimum order quantity is what decides whether this is viable for you at all. A good price against a batch you cannot sell inside its shelf life is not a good price — it is dead stock with a nice number on it. Ask for the MOQ before the rate, every time.

Mistake 6 — Assuming one plant can make your whole range

Red flag: any company offering every dosage form from a single facility.

Beta-lactam antibiotics legally require physically segregated premises. Ophthalmics and injectables need sterile lines. Ayurvedic products are licensed under a separate Act. A broad range always sits across dedicated sites — so the honest answer to "who makes your injectable?" is a different site name, not a shrug. If nobody will tell you which site each form comes from, you have learned something.

Mistake 7 — Treating documentation as optional

Red flag: hesitation over a certificate of analysis.

A batch manufacturing record and a certificate of analysis should arrive with every consignment as standard — not on request, not as a favour, not "we'll send it later." A manufacturer who has to be chased for a COA is telling you exactly how the next twelve months will go.

Mistake 8 — Not reading the liability clause

Who carries rejected material? Who carries damage in transit? Leakage and breakage between plant and warehouse is normally the transporter's liability, which is why freight insurance appears on the builty. Find that out before your first consignment arrives dented, not after.

Mistake 9 — Skipping the trademark

Your brand name is yours to clear. If it infringes, that is your recall and your loss — the manufacturer printed what you told them to print. Get the filing done before artwork, not after production.

Mistake 10 — Never asking who else that plant serves

This is the one that decides month nine. A plant making stock for one marketing company is inspected by the drug controller and nobody else. A plant manufacturing on contract for other pharmaceutical companies is audited by every one of them — on their schedule, to their standard, with the power to cancel.

When an API runs short, someone decides who gets the batch. You cannot negotiate that discipline into a contract. It is either already there or it is not.

Who manufactures for Vibcare

Vibcare Pharma is a PCD pharma franchise company. It does not manufacture. Manufacturing is done by Vibcare Healthcare Private Limited — a separate company under the same ownership, with its own plant, licences and website.

The site: Khasra No. 6/2/2, Kota Road, Dabkori, Panchkula 134103, Haryana. WHO-GMP certified by the State Drugs Controller-cum-Licensing Authority, FDA Haryana. Site Certificate No. 1/182-1Drug-I-2024, issued 24 October 2024. Licences MLF252023HR000004 and MLF282023HR000005, valid to 7 May 2028. 100,000 sq ft clean room, 750+ drug approvals.

Certified for four dosage forms: tablets, capsules and external preparations — all non beta-lactam — and oral liquids. It does not make beta-lactam antibiotics, ophthalmics, injectables, softgels, IV liquids, respules, DPI, nasal sprays, protein powders and sachets, or ayurvedic products, because it is not certified for them. That answers Mistake 6 before you have to ask it.

Not building your own brand? A PCD pharma franchise removes every mistake on this page — you sell an existing range in a monopoly territory, from ₹25,000, with no manufacturer to vet. Here is the difference.

Frequently asked questions

What are the red flags when choosing a third-party manufacturer?

A certification claim with no site name; vagueness about whose licence your product is made under; a rate quoted without a minimum batch size; any company offering every dosage form from one plant; and hesitation over supplying a certificate of analysis. Each one predicts a specific problem later.

What is the most common mistake in third-party manufacturing?

Asking for the rate before the site certificate. Everything else follows from it — you cannot judge a price until you know which plant makes the medicine and whether it is certified for your dosage form. Certificate first, rate second. Reluctance at that request is itself the answer.

Why should I ask who else a plant manufactures for?

Because it decides what happens in a shortage. A plant serving one marketing company is inspected by the drug controller alone. A plant manufacturing for other pharmaceutical companies is audited by all of them, with the power to cancel. That discipline cannot be written into your contract — it exists or it does not.

Who is liable for damaged stock in third-party manufacturing?

Manufacturing defects sit with the manufacturer; the site certificate states batch quality is their responsibility. Damage in transit, leakage or breakage, normally sits with the transporter, which is why freight insurance is charged on the builty. Read the liability clause before your first consignment, not after.